Pharmafile Logo

Patients and data tracking

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

ESMO 2025 – ensuring innovation isn’t lost in translation

This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community

Printed version of 'The participation equation'

Behind the scenes: why we created ‘The participation equation’

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

Cuttsy + Cuttsy

- PMLiVE

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

Inizio

- PMLiVE

Sandoz launches first and only multiple sclerosis biosimilar in US

The treatment is FDA-approved to treat MS and Crohn’s disease

- PMLiVE

Tonix launches new oral fibromyalgia treatment

Tonmya is the first approved treatment for adults with fibromyalgia in over 15 years

R:SQD logo

Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success

Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.

Cuttsy + Cuttsy

- PMLiVE

Optimised therapy to improve outcomes for heart attack and stroke patients

Personalising therapy promises to revolutionise the treatment of thrombosis

- PMLiVE

The new era of medical affairs: busting myths and supercharging strategic value

‘MA creates the scientific conditions for long-term, trustworthy commercial success’

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links